Company: SXTPW
Filing Date: 2025-07-16
Form Type: 424B4
Source: 0001213900-25-064472
Chunk: 0

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-16
Form: 424B4
Chunk 0
---
Filed pursuant to Rule 424(b)(4)

Registration No. 333-288550

<div align='center'>1,753,314 Shares of Common Stock

Series A-1 Warrants to Purchase up to 1,753,314 Shares of Common Stock

Series A-2 Warrants to Purchase up to 1,753,314 Shares of Common Stock

878,264 Pre-Funded Warrants to Purchase up to 878,264 Shares of Common Stock
Series A-1 Warrants to Purchase up to 878,264 Shares of Common Stock

Series A-2 Warrants to Purchase up to 878,264 Shares of Common Stock

Up to 6,141,420 Shares of Common Stock Issuable Upon Exercise of the Series A-1 Warrants, Series A-2 Warrants and Pre-Funded Warrants

60 Degrees Pharmaceuticals, Inc.</div>

We are offering 1,753,314 shares of common stock,
par value $0.0001 per share, and 878,264 pre-funded warrants, each having the right to purchase one share of common stock (the “Pre-Funded
Warrants”), together with accompanying Series A-1 warrants (the “Series A-1 Warrants”) to purchase up to an aggregate
of 2,631,578 shares of common stock, and Series A-2 Warrants (the “Series A-2 Warrants” and, together with the Series A-1
Warrants, the “Warrants”) to purchase up to an aggregate of 2,631,578 shares of common stock, pursuant to this prospectus.
The combined assumed public offering price for each share of common stock and accompanying Series A-1 Warrant and Series A-2 Warrant is
$1.90. Each Warrant will have an exercise price of $1.90 per share, will be exercisable upon issuance (the “Initial Exercise
Date”). The Series A-1 Warrant will expire on the fifth anniversary of the Initial Exercise Date. The Series A-2 Warrant will expire
on the eighteen (18) month anniversary of the Initial Exercise Date. The shares of common stock and any pre-funded warrants in lieu thereof
and accompanying Warrants are immediately separable and will be issued separately in this offering.

The Pre-Funded Warrants are being sold to purchasers
whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain
related parties, beneficially owning more